BCL2L1 and neoplasm: Our group has been actively developing other ways of targeting human tumor-infiltrating Treg cells to induce the degradation of BCL-XL using proteolysis-targeting chimera (PROTAC), which seems very effective for inducing anticancer immunity [145].